MarketCap
Alnylam Pharmaceuticals ALNY
$ 155.97
-0.34%
Facebook
X
Telegram
Alnylam Pharmaceuticals ROA Ratio | ALNY
Annual ROA Ratio Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.32 | -6.56 | -11.49 | -31.9 | -23.41 | -25.19 | -37.0 | -48.36 | -24.61 | -32.48 | -20.92 | -33.38 | -21.22 | -36.87 | -20.45 | -11.07 | -9.89 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.32 | -48.36 | -22.85 |
Quarterly ROA Ratio Alnylam Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.35 | 9.66 | 6.26 | 2.04 | -6.64 | -5.48 | -6.77 | -8.4 | -1.9 | -9.59 | -13.0 | -15.25 | -30.58 | -30.8 | -32.66 | -33.91 | -28.31 | -25.39 | -24.54 | -24.59 | -26.36 | -26.27 | -28.11 | -32.49 | -33.04 | -35.81 | -36.85 | -38.74 | -45.18 | -46.24 | -44.55 | -38.25 | -32.66 | -31.78 | -33.9 | -35.71 | -34.59 | -32.85 | -31.21 | -28.81 | -26.23 | -24.4 | -19.7 | -15.14 | -14.25 | -13.83 | -33.94 | -39.65 | -41.83 | -41.49 | -20.17 | -34.1 | -33.52 | -33.66 | -35.09 | -18.53 | -16.75 | -16.74 | -17.81 | -14.5 | -12.56 | -11.83 | -1.76 | -2.33 | -3.32 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.35 | -46.24 | -22.74 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-47.98 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-198.56 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-6.41 | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
-4.17 | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-79.54 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-166.66 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-98.29 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-80.09 | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-121.84 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.28 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-136.72 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-27.51 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-54.04 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-74.47 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
1.36 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-18.7 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
1.78 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
4.39 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-4.95 | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
-15.57 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
27.51 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-14.64 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
14.42 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
0.99 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-82.65 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-142.19 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-56.38 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
13.46 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-161.0 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-56.43 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-81.36 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-221.26 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-29.82 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-72.91 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.31 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-10.92 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
|
TFF Pharmaceuticals
TFFP
|
-176.62 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-13.02 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-2.77 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-28.79 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-6.89 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-29.75 | $ 1.09 | 6.37 % | $ 95 M | USA |